SEC Form 4 · accession 0001250853-18-000034
Kindred Biosciences, Inc. · KIN
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ervin Veszpremi
Director
Period of report
Jan 22, 2018
Accepted (ET)
Jan 24, 2018 · 9:58 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001561743
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F1 | $8.75 | Jan 22, 2018 | A | 75,000 | A | — | Jan 22, 2028 | Common Stock | 75,000 | 75,000 | D |
Explanation of responses
- F1The option will vest as to 25% quarterly following the date of grant.